Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00122434 · ClinicalTrials.gov registry record · Phase 2
Dose Finding Study in COPD
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 389
- Enrollment target
NCT00122434: Completed Phase 2 study, sponsored by Boehringer Ingelheim.
NCT00122434 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 389 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (192% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00122434, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 389 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the optimum dose of BEA 2180 BR inhalation solut ion delivered by the Respimat ? inhaler once daily for four weeks in patients with COPD.
Interventions
- DRUG tiotropium
- DRUG BEA 2180 BR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 389 participants |
| Start Date | 2005-07 |
| Phase | Phase 2 |
What the finished NCT00122434 record still lists
NCT00122434 is an interventional study that assigns participants to a tested intervention. The registered 389 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (192% higher).
The record links to 0 conditions, and to 2 interventions - of which tiotropium is the first listed.
NCT00122434 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00122434 about?
NCT00122434 is a clinical study titled "Dose Finding Study in COPD". The primary objective of this study is to determine the optimum dose of BEA 2180 BR inhalation solut ion delivered by the Respimat ? inhaler once daily for four weeks in patients with COPD.
What is the current status of trial NCT00122434?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 389 participants. The study started on 2005-07.
What interventions are being tested in trial NCT00122434?
The interventions under investigation include: tiotropium (DRUG), BEA 2180 BR (DRUG).
Who is sponsoring clinical trial NCT00122434?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00122434's enrollment target sits among peer trials
389 108th of 2000 higher than 1,892 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05431088 · 389 participants · Phase 2
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
- NCT00397111 · 390 participants
Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders
- NCT05335928 · 390 participants · Phase 3
Abatacept in Immune Checkpoint Inhibitor Myocarditis
- NCT05445960 · 390 participants · NA
Correlation Between Intraoperative Tourniquet Use and Limb pH, Functional Measures and Patient-reported Outcomes After Ankle Fracture Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia